Keywords
kinetic release
Kollidon
Abstract
The aim of the study was to investigate the modified release of a model substance, of tablets containing different types of Kollidon and particular additives. Additionally, the release kinetics and mechanism of prolonged release of certain tablet preparations were investigated. In this work, tablets containing different types of povidone (Kollidon CL, Kollidon 30, Kollidon SR and other excipients) were prepared by the direct compression technique. The results showed that tablets with fast disintegration and release should contain in their composition, Kollidon CL, lactose and Avicel, however, the use of β-CD instead of lactose or Avicel brings about a slight prolongation in the disintegration time of tablets and the release of an active substance. Furthermore, while other tablet compositions generated within this study must be considered as being prolonged release types, only two of these showed the best fitted mathematical models. Thein vitrodissolution data reveal that the dissolution profiles of the two formulations, one containing Kollidon SR with the addition of Kollidon 30, and the second with HPMC K15M, Kollidon 30, Kollidon CL and lactose, best fitted the Higuchi model. Moreover, the release mechanism of these two formulations plotted well into Korsmeyer-Peppas, indicating a coupling of drug diffusion in the hydrated matrix, as well as polymer relaxation – the so-called anomalous transport (non-Fickian).References
1. Abdelbary A., Elshafeey A.H, Zidan G.: Comparative effects of different cellulosic based directly compressed orodispersable tablets on oral bioavailability of famotidine. Carbohydr. Polym., 77, 799, 2009. [Web of Science]
2. Abed K.K. et al.: Formulation and optimization of orodispersible tablets of diazepam. AAPS PharmSciTech., 11(1), 356, 2010.
3. Akbari J. et al.: Influence of hydroxypropyl methylcellulose molecular weight grade on water uptake, erosion and drug release properties of diclofenac sodium matrix tablets. Trop. J. Pharm. Res., 10(5), 535, 2011.
4. Alves L.D. et al.: Solid dispersion of efavirenz in PVP K-30 by conventional solvent and kneading methods. Carbohydr. Polym., 104, 166, 2014.
5. Al-Zoubi N. et al.: Sustained release of diltiazem HCl tableted after co-spray drying and physical mixing with PVAc and PVP. Drug Dev. Ind. Pharm., 2, 1, 2015.
6. Attama A.A., Adikwu M.U., Nnamani P.O.: Delivery of diclofenac sodium via non-disintegrating bioadhesive tablets of paraffin wax. S T P Pharma. Sci., 13, 147, 2003.
7. Avachat A., Kotwal V.: Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate. AAPS PharmSciTech., 19, 8(4), E88, 2007.
8. Bourne D.W., Banker G.S., Rhodes C.T. (2002). Modern pharmaceutics 4th ed. New York: Marcel Dekker Inc.; p.67.
9. Cong W. et al.: Solid dispersion tablets of breviscapine with polyvinylpyrrolidone K30 for improved dissolution and bioavailability to commercial breviscapine tablets in beagle dogs. Eur. J. Drug Metab. Pharmacokinet., 39, 203, 2014.
10. Costa P., Lobo J.M.: Modelling and comparison of dissolution profiles. Eur. J. Pharm. Sci., 13, 123, 2001.
11. Desai C., Prabhakar B.: Development and evaluation of orally disintegrating tablets of cilostazol-β-CD inclusion complexes. Drug Dev. Ind. Pharm., 28, 1, 2014.
12. Desai P.M. et al.: Functionality of disintegrants and their mixtures in enabling fast disintegration of tablets by a quality by design approach. AAPS PharmSciTech., 15(5), 1093, 2014.
13. Draganoiu E., Andheria M., Sakr A.: Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets. Saudi Pharm. J., 19(1), 19, 2011.
14. Elwerfalli A.M. et al.: New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook. Curr. Drug Deliv., Mar 10 [Epub ahead of print], 2015.
15. European Pharmacopeia 8.0. Strasbourg: Council of Europe (2014); pp.285, 288,298, 2962, 3078.
16. Fini A. et al.: Fast dispersible/slow releasing ibuprofen tablets. Eur. J. Pharm. Biopharm., 69(1), 335, 2008.
17. Gohel M.C., Jogani P.D.: A review of co-processed directly compressible excipients. J. Pharm. Pharmaceut. Sci., 8, 76, 2005.
18. Gohel M. et al.: Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech., 26, 5(3), e36, 2004.
19. Grund J. et al.: The effect of polymer properties on direct compression and drug release from water-insoluble controlled release matrix tablets. Int. J. Pharm., 469, 94, 2014.
20. Hadjiioannou T.P., Christian G.D., Koupparis M.A. (1993). Quantitative calculations in pharmaceutical practice and research. New York: VCH Publishers Inc.; p:345.
21. Higuchi T.: Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci., 52, 1145, 1963.
22. Katsuno E. et al: Orally disintegrating tablets prepared by a co-processed mixture of micronized crospovidone and mannitol using a ball mill to improve compactibility and tablet stability. Powder Tech., 241, 60, 2013.
23. Kranz H., Wagner T.: Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations. Eur. J. Pharm. Biopharm., 62 70, 2006.
24. Kurkov S.V., Loftsson T.: Cyclodextrins. Int. J. Pharm., 30, 453(1), 167, 2013.
25. Late S.G., Banga A.K.: Response surface methodology to optimize novel fast disintegrating tablets using β cyclodextrin as diluent. AAPS PharmSciTech., 11(4), 1627, 2010.
26. Martindale: The complete drug reference (Accessed 01.06.2015). London: The Pharmaceutical Press, online: http://www.micromedexsolutions.com/home/dispatch.
27. Mishra D.N. et al.: Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets. Chem. Pharm. Bull., 54, 99, 2006.
28. Miyajima M. et al.: Factors influencing the diffusion-controlled release of papaverine from poly (L-lactic acid) matrix. J. Control. Release., 56, 85, 1998.
29. Muñoz H. et al.: Obtaining fast dissolving disintegrating tablets with different doses of melatonin. Int. J. Pharm., 467(1-2), 84, 2014.
30. Pabari R.M., Ramtoola Z.: Application of face-centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets. Int. J. Pharm., 430(1-2), 18, 2012.
31. Polish Pharmacopoeia X (2014). Warsaw: The Polish Pharmaceutical Society, pp: 388, 392, 395, 396, 443, 444, 3423, 3528.
32. Sahoo J. et al.: Comparative study of propranolol hydrochloride release from matrix tablets with KollidonSR or hydroxy propyl methyl cellulose. AAPS Pharm. Sci. Tech., 9, 577, 2008.
33. Siepmann F. et al.: Modeling drug release from PVAc/PVP matrix tablets. J. Control. Release., 141, 216, 2010.
34. Siepmann J., Peppas N.A.: Modeling of drug release from delivery system based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliver. Rev., 48, 139, 2001.
35. Strübing S., Metz H., Mäder K.: Characterization of poly(vinyl acetate) based floating matrix tablets. J. Control. Release, 126, 149, 2008.
36. Su S.F. et al.: In vitro and in vivo comparison of two diclofenac sodium sustained release oral formulations. Int. J. Pharm., 260(1), 39, 2003.
37. Wiranidchapong C. et al.: Plasticizing effect of ibuprofen induced an alteration of drug released from Kollidon SR matrices produced by direct compression. Drug Dev. Ind. Pharm., 41, 1037, 2015.
38. Yekpe K. et al.: Predicting the dissolution behavior of pharmaceutical tablets with NIR chemical imaging. Int. J. Pharm., 486, 242, 2015.
39. Zimmer Ł., Kasperek R., Poleszak E.: Modern polymers in matrix tablets technology. Polim. Med., 44(3), 189, 2014.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2016 Authors